BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jun 11, 2012
 |  BioCentury  |  Product Development

BRAF meets MEK

BRAF meets MEK

Study (n) Treatment (n) PFS (mos) ORR Occurrence of cutaneous squamous cell carcinoma (B) Grade 3 and higher SAEs with frequency >=5%
Zelboraf vemurafenib from Daiichi Sankyo Co. Ltd....

Read the full 252 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >